C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/46 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 14/725 (2006.01)
Patent
CA 2183066
The invention relates to certain specific binding partners, in particular ligands and fragments, variants, mutants or derivatives for a receptor on the surface of activated T-cells e.g. activated CD4+ T-cells. Exemplary ligands are based on a ligand designated ACT-4-L-h-1. Preferred fragments include extracellular domains of ligands. In addition the invention provides certain binding moieties with specificity for the above-mentioned specific binding partners. Suitable binding moieties include humanized and human antibodies to the ligand. The invention further provides nucleic acid segments which code for such a specific binding partner or binding moiety as well as expression vectors and cell lines which include these. The invention further provides pharmaceutical compositions containing the specific binding partners or the binding moieties together with methods of using the specific binding partners and binding moieties in the treatment of various diseases and conditions of the immune system. Also provided by the invention are methods of monitoring activated T-cells e.g. activated CD4+ T-cells using the specific binding partners or fragments thereof, together with kits for use in these methods.
L'invention porte sur certains partenaires de liaison spécifiques tels que des ligands et fragments, des variantes, des mutants ou leurs dérivés, pour un récepteur à la surface de cellules T activées, p. ex. du type CD4?+¿. Les ligands de l'exemple se basent sur un ligand appelé ACT-4-L-h-1. Les fragments préférés comprennent des domaines extracellulaires de ligands. L'invention porte, de plus, sur certaines fractions de liaison présentant une spécificité vis-à-vis des partenaires susmentionnés. Les fractions de liaison appropriées comprennent des anticorps humains et humanisés dirigés contre le ligand. L'invention porte également sur des segments d'acide nucléique codant pour de tels partenaires ou fractions de liaison ainsi que sur des vecteurs d'expression et des lignées cellulaires les incluant. L'invention porte encore sur des préparations pharmaceutiques contenant lesdits partenaires ou fractions de liaison et leur mode d'utilisation pour le traitement de différentes maladies et affections du système immunitaire. L'invention a enfin trait à des méthodes de suivi des cellules T activées, p. ex. du type CD4?+¿, à l'aide desdits partenaires de liaison ou de leurs fragments, et aux matériels utilisés dans ces méthodes.
Engleman Edgar George
Godfrey Wayne
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
The Board Of Trustees Of The Leland Stanford Junior University
LandOfFree
Ligand (act-4-l) to a receptor on the surface of activated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligand (act-4-l) to a receptor on the surface of activated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand (act-4-l) to a receptor on the surface of activated... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1729713